NIJMEGEN, The Netherlands – October 29, 2024: Khondrion, a pioneering clinical-stage biopharmaceutical company focused on developing transformative therapies for primary mitochondrial diseases (PMD), is pleased to announce its participation at two key industry events: the Bio-Europe Meeting in Stockholm (November 3–6) and the Investival Showcase Networking & Pitching Event in London (November 18). These events will feature Khondrion’s executive team, including CEO Prof. Dr. Jan Smeitink, Chief Scienfic Officer Dr. Herma Renkema, and Chief Financial & Business Officer Ir. Jasper Levink, as they provide updates on recent progress and plans.

Prof. Dr. Jan Smeitink, CEO at Khondrion, remarked, “We are excited to share our de-risked Phase 3 clinical development strategy that we have been developing in close collaboration with KOLs, patients and regulators. This trial represents a crucial step for both Khondrion and patients. We also look forward to exploring potential collaborations that will accelerate our mission of bringing impactful treatments to PMD patients worldwide.”

Khondrion’s lead drug candidate, sonlicromanol, is a first-in-class, brain-penetrant redox modulator with anti-inflammatory properties that mitigates the detrimental effects caused by mitochondrial dysfunction. Currently, sonlicromanol is advancing through late-stage development. We are initially focusing our efforts on PMD patients with the m.3243A>G variant—the most common genetic cause of multisystemic PMD, affecting an estimated 4.4 individuals per 100,000. There are currently no approved therapies for PMD patients with this genetic variant, highlighting the urgency of Khondrion’s work.

Khondrion’s broader objective is to expand sonlicromanol’s availability to address the wider PMD patient community. Primary mitochondrial diseases are the most prevalent genetic neurometabolic disorders. In Europe, the US and Japan combined, an estimated 250k individuals live with a Primary Mitochondrial Disease. With Orphan Drug Designations granted in both the U.S. and Europe, as well as Rare Pediatric Disease designation, Khondrion is at the forefront of PMD therapeutic development, offering new hope to a largely underserved patient population.

For more information about Khondrion’s participation in these events or to arrange a meeting, please contact:

Jasper Levink at levink@khondrion.com